Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs

Profusa (PFSA) has formalized an option agreement to acquire G3 Vision Labs and three subsidiary diagnostic companies. The deal grants Profusa the non-binding right to acquire the group, which generated approximately $111 million in 2025 net revenues. This represents a strategic expansion into the commercial diagnostics space, complementing Profusa's existing biosensing technology platform.

The option structure provides Profusa flexibility—management is not obligated to complete the acquisition and maintains control over timing and conditions. This approach mitigates downside risk while preserving upside optionality, a disciplined capital allocation strategy typical of early-stage growth companies. The inclusion of four diagnostic subsidiaries (Med Screen Laboratories, Dominion Diagnostics, Acutis Diagnostics) suggests meaningful operational scale and revenue diversification.

The $111 million revenue baseline from G3 indicates a material acquisition target, likely valued in the mid-to-high nine figures. Successful integration could meaningfully enhance Profusa's addressable market in digital health diagnostics, though execution risk remains. The announcement confirms earlier week guidance, suggesting investor confidence in deal progression.

Sector implication: Health Care and diagnostic technology faces consolidation tailwinds as integrated platforms gain competitive advantage. Profusa's move aligns with broader industry trend toward merging sensing technology with clinical diagnostic services, potentially creating stickier customer relationships and recurring revenue streams.